QBIOTICS GROUP LIMITED
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
QBIOTICS REPORTS 80% OBJECTIVE RESPONSE RATE IN INJECTED TUMOURS IN STAGE 1 OF PHASE IIA CLINICAL TRIAL OF TIGILANOL TIGLATE FOR SOFT TISSUE SARCOMA 2025-06-25 18:05
QBiotics' STELFONTA® Receives FDA Approval for Canine Mast cell Tumours 2020-11-17 11:51
QBiotics commercialises first tigilanol tiglate pharmaceutical product with launch of STELFONTA® 2020-04-28 14:43
QBiotics receives first registration for tigilanol tiglate with European Medicines Agency approval of Stelfonta(R) 2020-01-20 07:00
Publication of First In-Human Data Reveals Safety & Efficacy of Tigilanol Tiglate in Solid Tumours 2019-12-09 21:01
1